INSM Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -2.1%, SMA50 -8.69%, SMA200 5.82%). The stock’s 14-day RSI is 42.07 (neutral), while the ATR of 7.26 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -29.49% below its high and over 148.34% above its low. Average 10-day trading volume of 1.88 million shares is below the 3-month average of 2.72 million, indicating normal recent market interest.

Insmed Incorporated has 211.38 million shares outstanding. The public float is 190.42 million shares, elevated short interest at 5.00% of float. This equals 9.54 million shares. The short ratio is 3.67 days. Institutional investors hold 101.93% of the float. Insiders own 0.65%. Lewis William holds 301.18 thousand shares, SHAROKY MELVIN MD has 243.95 thousand shares and Wise John Drayton has 133.02 thousand shares. Over the past six months, insider transactions show net selling. They sold 136.38 thousand shares across 43 transactions.

Insmed Incorporated last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$159.64. This means the shares are trading below this model’s fair value.

Insmed Incorporated (NASDAQ:INSM) closed at $139.40 USD, losing -$4.45 (-3.09%) from the previous close of $143.85. The stock is currently mid-range between its 52-week high and low $60.40 and $212.75. With a market capitalization of about $30.05 billion, Insmed Incorporated is classified as a large-cap and shows market-like volatility (beta ~1.17). Key stats such as the average daily volume over the past year has been around 2.94 million shares, volume is running light vs its 52-week average. Headquartered in Bridgewater, NJ, Insmed Incorporated operates in the Healthcare sector and the Biotechnology industry. Led by CEO William H. Lewis, the company employs approximately 1,271 people and listed since June 01, 2000. Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases.

Insmed Incorporated generated EPS of -$6.40 over the past year. Five-year average earnings growth is -16.32%. The latest quarter delivered EPS of -$1.75. The next quarter is forecast at -$0.99. Next year's EPS is expected at $13.59. Analyst sentiment is bullish. Analyst rating data shows there are 21 Strong Buy ratings, 27 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $269.00 to $96.00. The high target offers 92.97% upside. The low target suggests -31.13% downside. The mean target is $183.92. This offers 31.94% upside. Insmed Incorporated earnings surprise history is a consistent trend of beating forecasts. The quarter that ended October 30, 2025, missed forecasts by 31.58%. The prior quarter beat by 31.78%. Over the last six quarters, Apple has recorded several small beats. These include 59.27% in August 08, 2024.

Insmed Incorporated trades at a P/E ratio of -23.49, slightly below the S&P 500 average, with a price-to-sales ratio of 49.9 and a price-to-book ratio of 40.59 reflecting a rich premium to book value. The P/FCF stands at -30.34, also below market averages. Compared to sector medians, Insmed Incorporated P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Our AI price prediction model suggests that Insmed Incorporated stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -2.69%, with price expected at $135.65 by March 25, 2026, within a range of $129.50 to $141.31 3-Month Outlook: Projected fall of -14.5%, reaching $119.19 by June 08, 2026, with a range of $117.46 to $120.86. 1-Year Outlook: Projected gain of 41.34%, with price at $197.03 by March 11, 2027, within a range of $188.90 to $205.25.

Insmed Incorporated (NASDAQ:INSM) shares are flat -6.05% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Insmed Incorporated trading at a premium to the broader market with a P/E of -23.49. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $113.94, suggesting -18.26% downside. Our AI forecast model points to short-term weakness (-2.69% over two weeks), a medium-term fall (-14.5% over three months), and a longer-term gain (41.34% over one year), with expected trading ranges indicating moderate volatility.